ArtemiFlow is a biotechnology Potsdam-based company founded in 2012 by Peter Seeberger.[1] The company produces and sells drugs containing the active ingredient artemisinin from Artemisia annua and its derivatives to fight malaria, cancer and other diseases.[2]

Production process

ArtemiFlow is one of Peter Seeberger's companies for the production of low-cost medicines. With his team, he developed a process to produce artemisinin in large quantities in a cost-effective and environmentally friendly way, especially to meet the needs of developing countries.[3][4][5] This was an innovative method as an alternative to Sanofi's genetic engineering one.[6] Artemiflow developed a reactor for novel artemisinin production[7] and developed higher-yielding plants in Kentucky in collaboration with the University Plants with higher yields.[8]

The new chemical production process is the first example of how not only the starting materials for making a drug or natural product are derived from plants. The catalyst, the tool that drives the reaction, also comes directly from plants.[9]

For developing the new process, Seeberger, Kerry Gilmore, and Andreas Seidel-Morgenstern were awarded the 2021 Science Prize for "Affordable Green Chemistry" by the American Chemical Society.[10]

Development

Initial difficulties were the large-scale implementation of the manufacturing process, the cultivation of annual mugwort in Vietnam and the financing of the start-up. According to the first CEO Dirk Pohlmann, the company was hoping for support from the Bill and Melinda Gates Foundation. The latter supported competing products from the Sanofi company made from genetically modified yeast. According to Pohlmann's account, the foundation's monopoly position in funding the international fight against malaria made it difficult for ArtemiFlow to gain a foothold.[10] In addition, simply announcing synthetic production dropped prices for producers, so less artemisinin was expected to be produced.[11]

COVID-19

Production on the potential use of artemisin against COVID-19[12][13][14] was controversial, in part because of possible conflicts of interest owing to Seeberger's leadership of ArtemiLife.[15] The critical article in the SZ was answered by an article in the German magazine Focus.[16]

References

  1. ↑ "biotechnologie.de". biotechnologie.de. Retrieved 2021-11-15.
  2. ↑ "Impact". Artemiflow. Retrieved 2021-11-15.
  3. ↑ "Pionier der Glykowissenschaften: Peter Seeberger erhält Stifterverbandspreis 2017". www.mpg.de (in German). Retrieved 2021-11-15.
  4. ↑ "Potsdamer Forscher revolutionieren Malaria-Wirkstoff". www.pnn.de (in German). Retrieved 2021-11-15.
  5. ↑ Hope for millions. Thanks to a German invention, an anti-malarial drug can be produced easily and cheaply. By Reiner Luyken, January 19, 2012 DIE ZEIT No. 4/201217
  6. ↑ Frank Odenthal (2021-11-13). "Backwash of innovation".
  7. ↑ "Wissenschaftspreis: Forschung zwischen Grundlagen und Anwendung - Preisträger 2017". Stifterverband (in German). 2019-06-23. Retrieved 2021-11-15.
  8. ↑ "UK to Grow Malaria-fighting Plants | University of Kentucky Research". www.research.uky.edu. Retrieved 2021-11-15.
  9. ↑ "Mit grüner Chemie gegen Malaria". Innovations Report (in German). 2018-02-21. Retrieved 2021-11-15.
  10. 1 2 Journalist, Volker Budinger, Diplom-Biologe, freier (2021-01-21). "Artemisinin-Herstellung wie in der Pflanze – nur schneller". DAZ.online. Retrieved 2021-11-15.{{cite web}}: CS1 maint: multiple names: authors list (link)
  11. ↑ Odenthal, Frank. "Backwash of innovation". FairPlanet. Retrieved 2021-11-15.
  12. ↑ Nie, C., Trimpert, J., Moon, S. et al. In vitro efficacy of Artemisia extracts against SARS-CoV-2. Virol J 18, 182 (2021). doi:10.1186/s12985-021-01651-8
  13. ↑ Laborjournal. "Gutes aus Grünzeug". Laborjournal (in German). Retrieved 2021-11-15.
  14. ↑ Zhou, Yuyong; Gilmore, Kerry; Ramirez, Santseharay; Settels, Eva; Gammeltoft, Karen A.; Pham, Long V.; Fahnøe, Ulrik; Feng, Shan; Offersgaard, Anna; Trimpert, Jakob; Bukh, Jens (2021-07-16). "In vitro efficacy of artemisinin-based treatments against SARS-CoV-2". Scientific Reports. 11 (1): 14571. doi:10.1038/s41598-021-93361-y. ISSN 2045-2322. PMC 8285423. PMID 34272426.
  15. ↑ Bartens, Werner; Dörries, Bernd. "Corona: Beifuß als Heilmittel gegen Covid-19?". Süddeutsche.de (in German). Retrieved 2021-11-15.
  16. ↑ "Pflanzenextrakte aus Beifuß sollen vor Covid-19 schützen – das steckt dahinter". FOCUS Online (in German). Retrieved 2021-11-15.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.